GPI to present four pieces of research at ISPOR

6 – 9 November 2022 – Vienna, Austria & Virtual

GPI will be attending and presenting our research at ISPOR, held at the Austria Center, Vienna, Austria on 6-9 November 2022. Our representatives will be onsite and on hand to discuss how GPI can optimise your pricing and market access decision-making in 2022 and beyond. In addition, GPI will be presenting four research posters that will be available throughout the conference.

  • Suitability of value-based price forecasting in a crowded landscape: a case study in rheumatoid arthritis
  • The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis
  • Regulatory and reimbursement landscape of CGTs across Europe
  • Solving the Chinese puzzle: what determines reimbursement price in China?

ISPOR Research Posters

Suitability of value-based price forecasting in a crowded landscape: a case study in rheumatoid arthritis

Objective: Value-based pricing supports HTA decision-making in England, France and Germany. Within a crowded therapeutic area, products may have the same HTA recommendations and benefit scores, but different prices. This research aimed to determine the suitability of using a value-price relationship to forecast price within a crowded landscape.


The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis

Objective: As a result of the introduction of the AMNOG law, the German healthcare system allows free-pricing of drugs within the first 12 months of launch. During this period, the G-BA evaluate a drug’s additional benefit versus comparators. The outcome of the assessment guides pricing negotiations for reimbursement, applicable 13th month after launch. Value and price are correlated to determine drug prices following G-BA evaluation, referred to as post-assessment prices, in Germany. The aim of the study was to assess the relationship between value and price for free-pricing and the post-assessment price of products in a crowded therapeutic area.


Regulatory and reimbursement landscape of CGTs across Europe

Objectives: Cell and gene therapies (CGTs) offer curative options for severe diseases at a high financial cost. As more CGTs enter the market, manufacturers and payers must understand the implications of the evolving landscape. This research explored the regulatory and reimbursement landscape of CGTs across France, Germany, Italy, and UK.


Solving the Chinese puzzle: what determines reimbursement price in China?

In China, price negotiations are mandatory for originator drugs to be listed on the National Reimbursement Drug List (NRDL). The process to determine a reimbursement price is not transparent; therefore, this study aims to explore various measures that can influence drug prices in a successful price negotiation.


ISPOR

Share the Article:

Sign up to our mailing list to be informed of the latest webinars